Physician profile
Manoj Khatore
NPI 1528140639
$6,057.00
in general payments reported to CMS, 2019-2025
25 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,761 · 2020: $246 · 2021: $467 · 2022: $709 · 2023: $1,137 · 2024: $707 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803 · Education: $70.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.46 |
| Education | $70.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $798.68 | 2019-2025 | Farxiga |
| Medtronic Vascular, INC. | $709.70 | 2019-2020 | |
| Abiomed | $681.39 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $514.65 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $489.69 | 2019-2023 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $343.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.42 | 2021-2025 | Jardiance |
| Amgen INC. | $302.88 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $278.05 | 2022-2025 | Verquvo, Belsomra |
| Esperion Therapeutics, INC. | $269.59 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $251.24 | 2022-2025 | Avvigo Guidance System, Rotapro, Varithena Administration Pack |
| Abbott Laboratories | $246.05 | 2019-2025 | Aveir |
| Pfizer INC. | $180.51 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $153.80 | 2019-2024 | Xarelto |
| Medtronic, INC. | $131.12 | 2022-2025 | Venaseal |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $111.49 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $72.67 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $46.47 | 2024 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $39.75 | 2019 | |
| Gilead Sciences, INC. | $34.80 | 2019 | |
| Heartflow, INC. | $26.97 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.49 | 2021-2024 | Lifevest |
| Chiesi USA, INC. | $19.42 | 2022 | |
| Biotronik INC. | $15.92 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Khatore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.